title: Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
abstract: Cystic fibrosis (CF) is an autosomal recessive inherited disease secondary to a defect in the CF transmembrane conductance regulator gene (CFTR). Mortality in CF is associated with impairment of lung function in which bacterial infection plays a fundamental role. The microorganism Pseudomonas aeruginosa (P. aeruginosa) is a marker of poor prognosis. Tobramycin was the first parenteral antibiotic to be used as inhaled medication in CF. Owing to its beneficial effects; it was subsequently used in designed inhaled formulations. The first formulation was the inhalation solution, which improved lung function, lowered hospitalization rates, and reduced the courses of intravenous antibiotic. However, the high associated costs and time necessary to administer the medication negatively affected quality of life. The recent development of tobramycin inhalation powder has optimized treatment. The dry powder inhaler is a simple device that reduces administration time and improves adherence. As there is no risk of bacterial contamination, disinfection is unnecessary.
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: E
authors.initials: E
authors.lastname: Vazquez-Espinosa
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: C
authors.initials: C
authors.lastname: Marcos
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: T
authors.initials: T
authors.lastname: Alonso
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: R M
authors.initials: RM
authors.lastname: Giron
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: R M
authors.initials: RM
authors.lastname: Gomez-Punter
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: E
authors.initials: E
authors.lastname: Garcia-Castillo
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: E
authors.initials: E
authors.lastname: Zamora
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: C
authors.initials: C
authors.lastname: Cisneros
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: J
authors.initials: J
authors.lastname: Garcia
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: C
authors.initials: C
authors.lastname: Valenzuela
authors.affiliation: a Pulmonology Department, La Princesa Institute for Health Research , Hospital Universitario de La Princesa , Madrid , Spain.
authors.forename: J
authors.initials: J
authors.lastname: Ancochea
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D058995:Dry Powder Inhalers; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011379:Prognosis; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D011788:Quality of Life; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D014031:Tobramycin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D014031:Tobramycin
keywords: Cystic fibrosis; Pseudomonas aeruginosa; chronic infection; tobramycin; tobramycin dry powder